This study focuses on hepatocellular carcinoma (HCC), a type of liver cancer that cannot be removed by surgery. Researchers are testing a new treatment combination: casdozokitug, toripalimab, and bevacizumab. Toripalimab and bevacizumab are drugs that help the immune system fight cancer and prevent blood vessels from feeding the tumor. The study's main goals are to check how safe and effective this combination is and to find the best dose for casdozokitug.
Key Points:
- Duration: The study will take several months, with multiple visits for treatment and monitoring.
- Eligibility: Participants must have HCC that cannot be surgically removed and no previous treatments for HCC.
- Compensation: Participants may receive compensation for their time and travel.
Participants should not have had prior therapy targeting IL-27 (a protein that can affect immune responses) or certain types of liver cancer like fibrolamellar or sarcomatoid HCC. The study excludes those with certain health conditions like uncontrolled fluid build-up in the body.